Taipei, Taiwan

Hsiu-Yi Cheng

This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Golden Biotechnology Corporation. Active years: 2016.

USPTO Granted Patents = 1 

% Patents Active = 100.0


 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovating Cancer Treatments: The Contributions of Hsiu-Yi Cheng

Introduction: Hsiu-Yi Cheng, a prominent inventor based in New Taipei, Taiwan, has made significant strides in the field of pharmaceutical innovation. His dedication to developing effective treatments for serious diseases has culminated in valuable contributions to cancer therapy.

Latest Patents: Cheng holds a patent for "Cyclohexenone compositions and process for making thereof." This groundbreaking invention outlines processes for preparing cyclohexenone compounds that are specifically useful in the fight against cancer and other diseases.

Career Highlights: Hsiu-Yi Cheng is currently associated with Golden Biotechnology Corporation, where he applies his expertise in chemistry and innovation. His work focuses on uncovering new therapeutic options that can lead to improved patient outcomes in oncology.

Collaborations: Throughout his career, Cheng has collaborated with esteemed colleagues, including Sheng-Yung Liu and Wu-Che Wen. These partnerships have fostered a dynamic environment for research and development, contributing to the advancement of cancer treatments.

Conclusion: Hsiu-Yi Cheng stands out as a dedicated innovator in the realm of cancer research. With his patent and collaborative efforts at Golden Biotechnology Corporation, he continues to make a meaningful impact on the future of disease treatment. His contributions represent a beacon of hope in the ongoing battle against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…